Ibaraki, Japan

Mika Tomita

This inventor holds 3 USPTO granted patents. Top assignee: Tsumura Co., Ltd.. Active years: 1995-1997.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 6(Granted Patents)


Location History:

  • Ibaraki, JP (1995)
  • Ibaraki-ken, JP (1997)

Company Filing History:


Years Active: 1995-1997

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations of Mika Tomita

Introduction

Mika Tomita is a notable inventor based in Ibaraki-ken, Japan. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target diabetes-related complications. With a total of 3 patents to her name, her work is recognized for its potential impact on medical treatments.

Latest Patents

Mika's latest patents include a chromone derivative and an aldose reductase inhibitor. These inventions are designed to exhibit superior inhibitory action on aldose reductase, which is crucial for treating various complications associated with diabetes, such as cataract, retinopathy, keratopathy, nephropathy, and neuropathy. The compounds she has developed are represented by specific chemical formulas, showcasing her expertise in medicinal chemistry.

Career Highlights

Mika Tomita is currently associated with Tsumura & Co., where she continues to innovate in the pharmaceutical sector. Her work is characterized by a commitment to improving health outcomes for individuals suffering from diabetes and its complications.

Collaborations

Mika has collaborated with esteemed colleagues such as Yasushi Igarashi and Takuji Yamaguchi, contributing to a dynamic research environment that fosters innovation and development.

Conclusion

Mika Tomita's contributions to the field of pharmaceuticals through her patents and collaborations highlight her role as a leading inventor in the industry. Her work not only advances scientific knowledge but also holds promise for improving the quality of life for many individuals affected by diabetes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…